---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Prevalence"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Prevalence. Topics: United States: diagnosed CSU period prevalence in three US databases, 2012 to 2018, Novartis-funded; United States: annual prevalence trend of diagnosed CSU, 2012 to 2018, Novartis-funded study; United States: cumulative prevalence of diagnosed CSU of 0.57% in adults in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors; United States: 12-month prevalence of self-reported physician-diagnosed CSU of 0.78% in adults, 2019 National Health and Wellness Survey, Novartis-funded; 14 further topics. 18 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/prevalence"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Chronic spontaneous urticaria

<a id="topic-2.2.1.2.2-1"></a>

### United States: diagnosed CSU period prevalence in three US databases, 2012 to 2018, Novartis-funded

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart.”
> “The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively.”
> “The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively.”
> “The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively.”
> “Our study reports the standardized period prevalence of diagnosed CSU among adults from 0.120% to 0.277% across three databases”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.2-2"></a>

### United States: annual prevalence trend of diagnosed CSU, 2012 to 2018, Novartis-funded study

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The annual standardized prevalence of diagnosed CSU among adults across three databases increased from 0.052% in 2012 to 0.191% in 2018.”
> “The standardized period prevalence of diagnosed CSU among pediatric patients ranged from 0.193% to 0.304% across the three databases.”
> “The findings of this study highlight a general increasing trend in the incidence and prevalence of diagnosed CSU over time among the US population.”
> “most of the patients (≥ 80%) were diagnosed with unspecified urticaria, followed by idiopathic urticaria and other urticaria”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.2-3"></a>

### United States: cumulative prevalence of diagnosed CSU of 0.57% in adults in HealthVerity claims, 2017 to 2022, Novartis-affiliated authors

> “Adults with a record of CSU diagnosis within the US HealthVerity claims database were eligible.”
> “Age- and gender-adjusted prevalence/incidence rates were calculated for January 2017 to December 2022.”
> “Overall, 200,298 patients were followed-up for a median of 2.3 years after diagnosis.”
> “Estimated cumulative prevalence of diagnosed CSU was 0.57% (women: 0.80%; men: 0.32%).”
> “Chronic spontaneous urticaria (CSU) is an unpredictable inflammatory skin condition with substantial clinical burden that affects 0.23% to 0.78% of the US population.”
> “US Medical Affairs, Novartis Pharmaceuticals Corp, East Hanover, New Jersey”

Source: [Riedl et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39694087/)

<a id="topic-2.2.1.2.2-4"></a>

### United States: 12-month prevalence of self-reported physician-diagnosed CSU of 0.78% in adults, 2019 National Health and Wellness Survey, Novartis-funded

> “This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.”
> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “Adults who self-reported receiving a diagnosis of CSU from a healthcare provider in the past 12 months were included in the analysis for all outcomes and for the calculation of the weighted 12-month prevalence of diagnosed CSU.”
> “Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU.”
> “The weighted prevalence (95% confidence interval) of diagnosed CSU was 0.78% (0.78%–0.78%).”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.2.2-5"></a>

### United States: chronic urticaria prevalence of 0.23% in adults, cross-sectional electronic health records analysis

> “To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.”
> “A cross-sectional analysis with electronic health records data for a demographically heterogeneous population-based sample of >55 million patients across all 4 census regions.”
> “The overall CU prevalence was 0.23%, or 230 CU cases/100,000 adults.”
> “There are >500,000 people estimated to have CU in the United States, most of whom are women or adults ≥40 years of age.”
> “Use of administrative data has the potential to underestimate burden.”

Source: [Wertenteil et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30872154/)

<a id="topic-2.2.1.2.2-6"></a>

### North America: chronic urticaria point prevalence of 0.1% in a global meta-analysis

> “The objective of this study was to systematically evaluate and summarize the prevalence of chronic urticaria by evaluating population-based studies worldwide.”
> “We performed a systematic search in PUBMED and EMBASE for population-based studies of cross-sectional or cohort design and studies based on health insurance/system databases.”
> “Eighteen studies were included in the systematic evaluation and 11 in the meta-analysis including data from over 86 000 000 participants.”
> “Asian studies combined showed a higher point prevalence of chronic urticaria (1.4%, 95%-CI 0.5-2.9) than those from Europe (0.5%, 0.2-1.0) and Northern American (0.1%, 0.1-0.1).”
> “The four studies that examined time trends indicated an increasing prevalence of chronic urticaria over time.”

Source: [Fricke et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31494963/)

<a id="topic-2.2.1.2.2-7"></a>

### United States: chronic urticaria prevalence range and female to male ratio in the Joint Task Force practice parameter

> “These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology.”
> “The prevalence of CU in the general population has been estimated to range from 0.5% to 5%; however, the true point prevalence, cumulative prevalence, and lifetime prevalence of CU have not been established.”
> “Studies have generally shown an increased prevalence in female subjects, with the female/male ratio of patients with CU ranging from 7:3 to as high as 4:1”

Source: [Bernstein et al. (2014)](https://doi.org/10.1016/j.jaci.2014.02.036)

<a id="topic-2.2.1.2.2-8"></a>

### United States: chronic urticaria prevalence in adults by sex, age, and race

> “To estimate standardized overall and sex-, age-, and race-specific prevalence estimates for CU among adults in the United States.”
> “The adjusted prevalence in women was 310 (95% confidence interval [CI] 307-312) cases/100,000 adults, more than twice that of men (146 [95% CI 143-148] cases/100,000 adults, P < .001).”
> “CU prevalence was highest among patients aged 40-49 years (256 [95% CI 252-261] cases/100,000 adults) and 50-59 years (246 [95% CI 242-251] cases/100,000 adults) compared with all other age groups (P < .0001).”
> “Adjusted prevalences for black (292 [95% CI 285-298] cases/100,000 adults) and other (331 [95% CI 323-338] cases/100,000 adults) patients were higher than that for white patients (262 [95% CI 260-264] cases/100,000 adults; P < .001).”

Source: [Wertenteil et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30872154/)

<a id="topic-2.2.1.2.2-9"></a>

### United States by age: higher diagnosed CSU prevalence in pediatric than adult populations, Novartis-funded study

| Database and period | Adults (aged 18 years or older), prevalence (95% CI) | Pediatric patients (aged under 18 years), prevalence (95% CI) |
| --- | --- | --- |
| Optum EHR, 2012 to 2018 | “0.120% (0.119–0.120)” | “0.193% (0.191–0.195)” |
| Optum CDM, 2012 to 2018 | “0.277% (0.275–0.279)” | “0.304% (0.300–0.308)” |
| MarketScan, 2012 to 2017 | “0.256% (0.248–0.265)” | “0.264% (0.261–0.266)” |

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

> “This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.”
> “The prevalence of CSU in the present study was higher among pediatric patients than among adults across all databases.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland.”

Source: [Geissbühler et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12085360/)

<a id="topic-2.2.1.2.2-10"></a>

### United States: age at diagnosis and sex of adults with self-reported diagnosed CSU, Novartis-funded survey

> “This cross-sectional study used data from the 2019 NHWS, a nationally representative sample of the US population.”
> “The mean (standard deviation [SD]) age at diagnosis was 37.0 (17.1) years, and 51.7% of respondents were female.”
> “This research was funded by Novartis Pharma AG, Basel, Switzerland”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.2.2-11"></a>

### Female predominance from age 31 years in the international CURE registry

> “We analysed Chronic Urticaria Registry (CURE) data, an international real‐world registry for patients with chronic urticaria.”
> “Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female.”
> “Statistically significant female predominance started at age 31 (<0.001).”
> “CSU demonstrates a pronounced sex disparity, with females being disproportionately affected—evidenced by at least twofold higher incidences in females compared with males.”

Source: [Kocatürk et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12723574/)

<a id="topic-2.2.1.2.2-12"></a>

### Children: no sex difference in chronic urticaria prevalence under age 15 years

> “Women were slightly more affected than men, whereas in children < 15 years we did not find a sex-specific difference in the prevalence.”

Source: [Fricke et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31494963/)

<a id="topic-2.2.1.2.2-13"></a>

### Children in five European countries: one-year diagnosed CSU prevalence of 0.75% from a physician survey

> “A physician-based online survey was conducted in 5 European countries (United Kingdom, Germany, Italy, France, and Spain) assessing the annual diagnosed prevalence, disease characteristics, and treatment patterns in the target population.”
> “Across 5 European countries, the one-year diagnosed prevalence of CU and CSU in pediatric patients was 1.38% (95% CI, 0.94-1.86) and 0.75% (95% CI, 0.44-1.08), respectively.”

Source: [Balp et al. (2018b)](https://pubmed.ncbi.nlm.nih.gov/29679413/)

<a id="topic-2.2.1.2.2-14"></a>

### Germany: lifetime and 12-month prevalence of chronic urticaria in a representative Berlin population survey

> “A questionnaire survey was sent to a representative cross-sectional sample of 13,300 inhabitants of Berlin, Germany, of whom 4093 responded.”
> “Lifetime prevalence rate of urticaria was 8.8% (95% CI 7.9-9.7%) for all types of urticaria.”
> “Lifetime prevalence for CU was 1.8% (95% CI 1.4-2.3%), and prevalence for the 12 months before assessment was 0.8% (95% CI 0.6-1.1%), and 70.3% were female.”

Source: [Zuberbier et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456386/)

<a id="topic-2.2.1.2.2-15"></a>

### Italy: annual prevalence of CSU in a general practitioner database, 2002 to 2013

> “The study population was formed by patients aged ≥ 15 years, registered with a total of 700 general practitioners, homogeneously distributed across Italy.”
> “The annual prevalence of CSU ranged from 0·02% in 2002 to 0·38% in 2013.”
> “For both prevalence and incidence rates, female patients outnumbered male.”

Source: [Lapi et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26872037/)

<a id="topic-2.2.1.2.2-16"></a>

### Italy: annual prevalence of CSU in primary care, 2002 to 2022

> “A cohort of patients aged 15 years and older with newly diagnosed CSU was identified from Italian primary care data from January 1, 2002, to September 30, 2022.”
> “Annual CSU prevalence ranged from 0.41% in 2002 to 0.35% in 2022.”

Source: [Lapi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42702025/)

<a id="topic-2.2.1.2.2-17"></a>

### Global: urticaria prevalence and female share in the Global Burden of Disease 2021 study

> “Globally, the total number of urticaria cases increased from 47,949,600 (42,267,752 − 54,859,773) in 1990 to 66,483,473 (59,240,738 − 74,912,351) in 2021.”
> “Meanwhile, the prevalence rate decreased from 899.01 (792.48-1028.56) per 100,000 population in 1990 to 842.49 (750.70-949.30) per 100,000 population.”
> “In 2021, females accounted for 58.94% of the total urticaria cases, with a female/male ratio of 1.44.”

Source: [Tan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12333250/)

<a id="topic-2.2.1.2.2-18"></a>

### Global: lifetime prevalence of urticaria

> “The lifetime prevalence of acute urticaria is estimated to be approximately 20%.”
> “Urticaria is a frequent disease affecting up to 20% of the world population at some point during their lifetime, with over half of those patients reporting angioedema, and the global prevalence continues to increase”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
